Objective: To explore the clinical efficacy and safety of paclitaxel liposome injection and common paclitaxel in the treatment of gastric cancer. Method: Pubmed

EBM

EMBase

Cochrane Library

CNKI and other related database were retrieved for randomized controlled trials (RCTs) on the paclitaxel in treatment of gastric cancer

limited to Chinese and English versions. Two reviewers screened the literature and extracted data independently according to the inclusion and exclusion criteria

and then used the Jadad scale to evaluate the quality of literature. Result: The 6 RCTs

355 patients in total were included for paclitaxel liposome VS common paclitaxel in the treatment of gastric cancer. Meta-analysis results showed that paclitaxel liposome had higher effective rate in the treatment of gastric cancer [OR=1.42

95%CI (0.92

2.18)

P=0.11]

and higher benefit rate [OR=1.92

95%CI (1.14

3.22)

P=0.01]

with statistical difference in benefit rate. In respect of safety

paclitaxel liposome caused fewer adverse reactions such as joint pain [OR=0.09

95%CI (0.04

0.36)

P<0.000 01]

muscle pain [OR=0.07

95%CI (0.01

0.36)

P=0.001]

facial flushing [OR=0.06

95%CI (0.01

0.26)

P=0.000 2] than common paclitaxel

with statistically significant difference. Conclusion: Paclitaxel liposome has higher benefit rate and more obvious effect than common paclitaxel in treatment of gastric cancer

and meanwhile

it can significantly alleviate the toxic side effects and improve the care experience for patients.